Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and effectiveness of baricitinib in treating severe or very severe alopecia areata, a type of hair loss, in children aged 6 to less than 18 years. This Phase 3 trial includes children and adolescents with severe alopecia areata lasting at least one year and aims to understand how baricitinib helps improve their condition compared to placebo. Participants will be randomly assigned to one of three groups baricitinib high dose, baricitinib low dose, or placebo, all taken orally. The study includes a 5-week screening period, a 36-week double-blind treatment period, an approximately 2-year long-term extension period, and a 4-week post-treatment follow-up. Some participants may qualify for additional treatment after the extension period lasting up to 180 weeks. During the study, participants will have regular assessments including hair loss severity scores, patient and clinician reported outcomes, anxiety and depression scales, and pharmacokinetic tests. Safety and effects on quality of life will be monitored throughout, with follow-ups after treatment ends. Total participation may last several years depending on the study phase and extension.
Actively Recruiting
Researchers are evaluating the efficacy and safety of deuruxolitinib in Japanese adults aged 18 to 65 who have severe alopecia areata with at least 50% scalp hair loss. This Phase 3 study includes a double-blind, randomized, placebo-controlled treatment period followed by an open-label extension. The trial aims to assess how well deuruxolitinib works and its safety in this population. Participants will be randomly assigned to receive either deuruxolitinib 8 mg orally twice daily or a matching placebo during the initial 24-week double-blind treatment phase. Following this, all participants will enter a 52-week open-label extension where they will receive deuruxolitinib 8 mg twice daily. This design allows comparison between the drug and placebo initially, then all participants receive the active drug. Throughout the study, participants will undergo regular assessments including measuring scalp hair loss using the Severity of Alopecia Tool SALT score at various weeks. Patient satisfaction and clinician-reported outcomes will also be evaluated. Safety monitoring will include tests for infections and organ function. The primary outcome is the percentage of subjects achieving a SALT score of 20 or less at Week 24. Overall participation lasts up to 76 weeks including both treatment periods.